Research in MS is progressing at a remarkable rate, with more potential therapies in the pipeline than at any other time in history. The National MS Society is a driving force of MS research, supporting and stimulating world-class research into ways to prevent, better treat and cure this unpredictable disease of the brain and spinal cord. Learn how far we’ve come, where we’re going and what the Society and others are doing to move toward a world free of MS.
Research News
Bulletins about research progress from around the world
New Funding Opportunity
The Society announces a new Request for Applications for the initial development of prospective studies on the risk factors for progression in MS.
Research We Fund
The who, what, where, why and how of the Society’s cutting-edge MS research
Intriguing Leads on the Horizon
Exciting leads and clinical trials researchers are pursuing
Clinical Trials
These treatment trials urgently need patients willing to participate
Researchers Need You
How you can help move research forward by getting involved
How Far We’ve Come
History and timeline of progress, and how the Society has helped propel these advances
Recent Research News
UPDATE: CCSVI or Blood Flow in the Brain and Venous Insufficiency in MS – Society Leaders Meet with Dr. Zamboni Today. Research Proposals Received from Around the World on February 9th Grant Request Deadline
Feb 09, 2010
CCSVI or Blood Flow in the Brain and Venous Insufficiency in MS – National MS Society Leaders Meet with Dr. Zamboni Today. Research Proposals Received from Around the World on February 9th Grant Request Deadline.
MS Trial Alert: Study of Oral Teriflunomide (HMR1726) Recruiting People with Relapsing Forms of MS Worldwide
Feb 08, 2010
Summary: Investigators worldwide are recruiting 1110 people with relapsing forms of multiple sclerosis (MS) for a study comparing two doses of teriflunomide (HMR1726), an investigational, oral MS medication, and inactive placebo. For the purposes of this study, "relapsing forms of MS" would include individuals who have experienced one MS attack in the past one year or two MS attacks in the past two years. The study, known as the “TOWER” study, is sponsored by Sanofi-Aventis.
Update on Tysabri and PML: UPDATED FEBRUARY 5
Feb 05, 2010
According to information released by Biogen Idec, as of January 12, 2010, there have been 31 confirmed cases of PML among people who have used Tysabri after it became available for prescription in July 2006. Some details about 24 of the cases are provided here.
UPDATE: FDA Approves Fampridine SR, Now Called Ampyra,™ to Improve Walking for People with All Types of MS -- Wholesale Price Announced, New Webcast Available from Society
Feb 03, 2010
The FDA has approved Ampyra™ (dalfampridine, formerly known as fampridine SR, from Acorda Therapeutics) for its ability to improve walking in people with any type of MS. This is the first therapy specifically approved to treat a symptom of MS, and it represents a big step forward for the many people who may benefit.
MS Trial Alert: Recruiting Nationwide for Study of Copaxone in Patients with First Episode of Acute Optic Neuritis
Feb 02, 2010
Summary: Investigators at sites throughout the United States are recruiting 200 people who have experienced one episode of acute optic neuritis, to determine whether nerve fiber loss can be minimized with administration of glatirmamer acetate (Teva Pharmaceutical Industries) treatment. Optic neuritis is an inflammation of the optic nerve, and often is the first symptom of multiple sclerosis. The study is funded by Teva Pharmaceutical Industries.